CDK4 and breast carcinoma: To confirm the biological significance of the correlations of these transcripts with sensitivity to CDK4/6 inhibitors, we constructed ENST00000257904 and ENST00000547281 transcript expression plasmids using the pCDNA3.1 vector (Fig. 6b), transfected the plasmids into MCF7 cells (a model of luminal A-type breast cancer, a subtype for which ribociclib treatment is used, Fig. 6c), and detected the sensitivity of the plasmid-transfected cells to ribociclib.